Category Archives: Myocardial Infarction

Heat-shock proteins are a family of proteins which are upregulated in response to stress stimuli including inflammation, oxidative stress, or ischemia. Protective functions of heat-shock proteins have been studied in vascular disease models, and malfunction of heat-shock proteins is associated with vascular disease development. Continue reading →

TMRR, in its recent market report, suggests that the Post-Myocardial Infarction market report is set to exceed US$ xx Mn/Bn by 2029. The report finds that the Post-Myocardial Infarction market registered ~US$ xx Mn/Bn in 2018 and is spectated to grow at a healthy CAGR over the foreseeable period. This Post-Myocardial Infarction market study considers 2018 as the base year, 2019 as the estimated year, and 2019 2029 as the forecast timeframe Continue reading →

The report on the Myocardial Infarction Therapeutics Market published by Future Market Insights (FMI) provides a clear understanding of the flight of the Myocardial Infarction Therapeutics Market over the forecast period 2016 2026. The study introspects the various factors that are tipped to influence the growth of the Myocardial Infarction Therapeutics market in the upcoming years. The current trends, growth opportunities, restraints, and major challenges faced by market players in the Myocardial Infarction Therapeutics Market are analyzed in the report Continue reading →

Image: Interventional cardiology may not provide benefits to ischemia sufferers (Photo courtesy of iStock) The ISCHEMIA study (funded by the U.S. Government at a cost of USD 100 million and conducted at 320 sites in 37 countries), randomly assigned 5,179 stable patients with moderate-severe ischemia to early invasive coronary catheterization followed by percutaneous coronary intervention (PCI) or coronary bypass surgery plus OMT, or to OMT alone. Angina frequency at baseline was none in 34%, several times per month in 44%, and daily or weekly in 22%. Continue reading →

Myocardial Infarction Drug Market 2018: World Trade Insights by way of World Gamers, Regional Segmentation, Expansion, Packages, Main Drivers, Price and Foreseen until 2024 The document supplies each quantitative and qualitative data of world Myocardial Infarction Drug marketplace for duration of 2018 to 2025. As in step with the research supplied within the document, the worldwide marketplace of Myocardial Infarction Drug is estimated to expansion at a CAGR of _% throughout the forecast duration 2018 to 2025 and is predicted to upward thrust to USD _ million/billion by way of the tip of 12 months 2025. Continue reading →

Amarin Corporation plc AMRN announced that the European Medicines Agency has validated and accepted its marketing authorization application (MAA) for Vascepa (icosapent ethyl). The MAA seeks approval for the drug in Europe as a treatment to reduce the risk of cardiovascular events in high-risk patients with cholesterol levels controlled with statin treatment but elevated triglycerides and other cardiovascular risk factors Continue reading →

Cyberattacks on the healthcare industry have spiked. More than 90% of healthcare organizations have experienced a breach of some sort in the last five years Continue reading →

RATIONALE: Coronaryangiography (CAG) findings of acute myocardial infarction (AMI) in pregnant women are characterized by a high incidence of normalcoronaryarteries. Continue reading →

Dublin, Nov. Continue reading →

Next story: Published on November 29, 2019 The prevalence of Cardiovascular Disease has progressively increased in India over the last few decades and is now the major cause of death in the country. Myocardial Infarction (MI), also known as a heart attack, takes place when the coronary artery becomes blocked leading to death of heart muscle Continue reading →